Sesen Bio Reports First Quarter 2019 Financial Results and Updated, Preliminary Primary and Additional Secondary Endpoint Data from Phase 3 VISTA Trial for High-Risk Non-Muscle Invasive Bladder Cancer

Stock Information for Sesen Bio Inc.

Loading

Please wait while we load your information from QuoteMedia.